BIOLOGICAL TESTING FACILITY - RESEARCH AND DEVELOPMENT OF PRECLINICAL CONTRACEPTIVES

生物测试设施 - 临床前避孕药的研究和开发

基本信息

批准号：
10013411
负责人：
TOUFAN PARMAN
金额：
$ 85.75万
依托单位：
SRI INTERNATIONAL
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-05 至 2020-09-27
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10013411
关键词：
Animals Area Biological Assay Biological Testing Chemicals Clinical Clinical Research Clinical Trials Clinical Trials Network Contraceptive Agents Contraceptive Devices Contraceptive methods Contractor Development Documentation Drug Formulations Endocrine Enrollment Evaluation Excretory function Formulation Implant In Vitro Injectable Investigational Drugs Investigational New Drug Application Metabolism Methods Mission National Institute of Child Health and Human Development Oral Ovulation Pharmaceutical Preparations Pharmacologic Substance Phase Plasma Play Process Production Program Development Protocols documentation Reporting Research Personnel Research Support Role Route Safety System Testing Therapeutic Agents Time Toxic effect Toxicology Woman absorption chemical synthesis clinical lot clinical material design drug candidate drug development in vitro Assay in vivo lot production men novel therapeutics pharmacokinetics and pharmacodynamics pre-clinical preclinical development product development programs recruit research clinical testing research facility sperm cell sperm function stability testing

项目摘要

Within NICHD/DIPHR, the Contraceptive Development Program (CDP) supports research to develop compounds that can disrupt normal ovulation, sperm production or sperm function for the purpose of developing safe, effective and affordable contraceptives for men or women. The Biological Testing Facility (BTF) is designed to permit rapid evaluation of new compositions-of matter, drug formulations, delivery systems, and devices for contraceptive and endocrine activity. The BTF provides overall project management and the capabilities to support all phases of preclinical activities pursuant to development of new contraceptive methods: these include, but are not limited to in vitro and in vivo assays, plasma and microsomal stability studies, absorption, distribution, metabolism, excretion and toxicity (ADMET), pharmacokinetic (PK) and pharmacodynamic (PD) profiling, animal activities and studies, manufacture of active pharmaceutical ingredients (APIs), process and product development, formulation, clinical lot production, preclinical enabling studies and associated tasks leading to the filing of investigational new drug (IND) applications. Compounds formulated by the BTF are prepared under current Good Manufacturing Practices (cGMP) to allow clinical evaluation in the CDP Contraceptive Clinical Trials Network (CCTN). The CCTN investigators have develop protocols to evaluate the drug candidates identified as high priority by the Program. The BTF has been working with the CORs for the Chemical Synthesis Facility and the CCTN and with the investigators in the CCTN to develop and test the appropriate formulations for clinical batches of the candidate compounds. The next clinical study for each candidate drug is dependent on timely receipt of clinical batches to begin the process of recruitment and enrollment. Drugs that are currently in ongoing clinical trials require stability testing of the clinical formulations. The Biological Testing Facility plays a critical role in the drug development mission of the CDP.

在NICHD/DIPHR中，避孕开发计划（CDP）支持开发可破坏正常排卵，精子产生或精子功能的化合物，以开发男性或女性的安全，有效和负担得起的避孕药。生物测试设施（BTF）旨在快速评估物质，药物配方，输送系统和避孕和内分泌活性的设备。 BTF提供了总体项目管理和支持根据新避孕方法发展的临床前活动的所有阶段的能力：其中包括但不限于体外和体内测定，血浆和微粒体稳定性研究，抽象，抽象，分布，分布，极端和毒性（Admet and Intial（Admet），PERACKINIC（PARNAC）和制药（PK）（PK）（PK）（PS）（PARNAC）（PARNAC），并且活性药物成分（API），过程和产品开发，制定，临床批次生产，临床前促进研究以及相关任务，导致提出研究新药（IND）应用。由BTF制定的化合物是根据当前良好的制造实践（CGMP）制备的，以允许在CDP避孕临床试验网络（CCTN）中进行临床评估。 CCTN研究人员已经开发了协议，以评估该计划确定为高优先级的候选药物。 BTF一直在与CORS合成化学合成设施和CCTN以及CCTN中的研究人员，以开发和测试适当的公式，以了解候选化合物的临床批次。每种候选药物的下一项临床研究取决于及时接收临床批次，以开始招募和入学过程。目前正在进行的临床试验的药物需要对临床公式进行稳定测试。生物测试设施在CDP的药物开发任务中起着至关重要的作用。